Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. - Wikidata - awgldk - TriplyDB

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

http://www.wikidata.org/entity/Q34611141

about

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma Advances in the treatment of relapsed or refractory Hodgkin's lymphoma A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Hodgkin lymphoma, version 2.2015.Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma.ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin's lymphoma therapy: past, present, and future.Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients Management of fertility in patients treated for Hodgkin's lymphoma.Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial Primary melanoma of the prostate: case report and review of the literature.Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues Current concepts and controversies in the management of early stage Hodgkin lymphoma.Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.FDG-PET/CT based response-adapted treatment.Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials Novel therapies for Hodgkin Lymphoma.Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient.Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

P2860

Q24234975-DFC850B7-2A38-46BB-8341-9D6D8AE8C7A8 Q26822480-5CC33462-E62F-45DB-9F07-15C95CA2DEEC Q27694504-0F061125-77D0-42E5-9057-40329406F3EB Q30538453-7C20395A-D607-4ED2-A21E-7FFFB7BCA0D3 Q30538788-288E4A41-F897-4870-B982-6464386A9A28 Q30769157-9B9C3B34-EF46-425F-8540-7AD54C061E85 Q33388187-30124055-2A8E-40F7-A59B-6CD9F4B056F1 Q33432165-545B1281-C758-49F4-A485-4144FDE1C41B Q33442092-D9C856BB-BA69-4A4A-A823-677BFB226E20 Q33704061-D2C4C1E9-C8FF-4164-9CE7-F30B4261C8AF Q33935351-581C6D54-D8FD-4F51-AC35-5CC6C72BF213 Q34194160-23818BA7-FA74-4EA1-B433-A02DCC8863DA Q34296914-E6384D7C-AB94-41AF-91BC-F48C12B2DAD4 Q34475763-07DF088D-EDEC-47C4-B3FD-DF7341C9A5D1 Q34495333-BEF25493-5C28-4AFC-9429-93C27508996A Q34640031-7ACCDF00-5D12-4A62-A694-D6AFC96E6984 Q34662648-3301A7A9-D1A9-4E2C-8C10-58B72DED3B99 Q34707420-CB525223-67CD-4DC9-AC0A-EEC4E70517F8 Q35038852-B9F4CCBB-3BEB-42FB-A9A7-076CB55D1D8C Q35091669-DE4564BE-6962-47A1-9012-A881C644CF2E Q35093659-636C191B-E3A5-4CD6-8FFA-D8A66C58BC16 Q35528686-5F3B5132-0C1A-41A9-96DD-6927CDFD998E Q35602142-81CDA52F-A750-4D76-B473-BFBDAAC25F04 Q35671369-D67C3418-568D-462B-9B70-3F7381B7A14F Q35690088-1D063DDF-E172-4715-AED5-D46666908CC3 Q35717972-7AEBD224-7DC5-41D9-8477-510FEEF281A1 Q35986604-AB0FF7A1-6FF7-4DC4-AF51-14FE7C8657CB Q36006435-2B827254-2FB4-477B-96C7-416567E5D3A4 Q36010259-DB1E712F-A7C0-471D-B273-F6E352856183 Q36061643-BF983967-216D-47C1-8C8C-D61D1ED61C2F Q36094726-E358B27A-3414-4B04-9927-8F702A07486B Q36164491-3AEA5043-1675-4D7D-8FF3-DD73ABA91A51 Q36286595-464D1AA7-1DCF-4C7C-A0A9-8F196253D0AA Q36557883-8303D7F8-39C7-4E75-ACB9-9852491F3507 Q36589635-961FDCBA-904C-45E9-A3DD-519876D2C40D Q36612532-4B06B318-69F0-4C53-B997-7EBF185C4254 Q36612560-4397A044-6882-41D3-B06A-5F223ACFFE4D Q36615084-AA51E1B6-984F-4F21-A2D4-FE07FEEB6E07 Q36706850-74436783-120C-4BD9-9E6C-EF07A1D57A1F Q37126978-ECD1F06B-760C-4437-A63C-9167BBE2A837

P2860

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

http://www.wikidata.org/entity/Q34611141

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@ast

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@en

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@nl

type

label

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@ast

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@en

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@nl

prefLabel

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@ast

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@en

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@nl

P1433

Q34611141-CEEADA02-207A-4FA2-8EE5-AD6E82F06097

P1476

Q34611141-075B614D-F749-46F0-8E2A-849A211535FE

P2093

Q34611141-0AE988F9-423C-412A-99B1-C7DDDCF7D2F3

Q34611141-1C8CA87E-63FC-4812-93D8-DB871DA1400C

Q34611141-4FE6720F-7CDB-4CD7-9E78-5F351506A603

Q34611141-6FA27089-8C6D-4A37-8FE1-CE4753B0B598

Q34611141-73D5C47A-BF43-4D77-B7A9-2856B23C2FED

Q34611141-801DDB55-8A67-4582-80F0-7DA50200384C

Q34611141-8F24B7B6-5A69-481C-9FDB-28F4E39B0604

Q34611141-93FD9C32-DA79-4B4E-A56B-7962FFD99E1E

Q34611141-9DDA4E8D-9693-4649-88BF-D5A9862055E3

Q34611141-A14D55DA-F476-47B2-8FBC-66E4F31D1C90

P304

Q34611141-861E6910-6678-4489-B244-080C84930ADB

P31

Q34611141-65E03ED5-4090-4810-B866-DBEC51167446

P356

Q34611141-71FD6654-2996-48C9-8120-33548D129AF9

P407

Q34611141-8C870639-D5C7-43E5-9696-29311705D142

P433

Q34611141-D702CD4B-23CD-463B-9731-1152ED35D677

P478

Q34611141-900FDF87-A9DD-42CF-B02A-EB806A5EC04D

P50

Q34611141-4C9E7EDA-5F17-43A5-A282-6FDE14DDC425

Q34611141-81A2CEC7-1361-4724-BBFB-BB8BF4BF3F57

Q34611141-C14E43FA-95B6-4029-B972-87D7BB1321C8

Q34611141-E708D283-4F79-4F62-A1DE-A3CD3AC87B3F

P577

Q34611141-E43C2976-F516-4537-8114-5AF8A38AD2AE

P5875

Q34611141-20733EA1-418A-4759-9452-C1EC43159D8A

P698

Q34611141-0E52655C-FC74-4FC7-A692-537A5C3F3576

P921

Q34611141-A1A34439-DAD1-41E6-A5CA-E448A2F24491

P356

JCO.2008.19.8820

P1433

Journal of Clinical Oncology

P1476

Escalated-dose BEACOPP in the ...... llow-up of the GHSG HD9 study.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Andreas Lohri

http://www.w3.org/2001/XMLSchema#string

Bernd Dörken

http://www.w3.org/2001/XMLSchema#string

Jeremy Franklin

http://www.w3.org/2001/XMLSchema#string

Markus Löffler

http://www.w3.org/2001/XMLSchema#string

Martin Bentz

http://www.w3.org/2001/XMLSchema#string

Martin Wilhelm

http://www.w3.org/2001/XMLSchema#string

Mathias Hänel

http://www.w3.org/2001/XMLSchema#string

Mathias Rummel

http://www.w3.org/2001/XMLSchema#string

Orhan Sezer

http://www.w3.org/2001/XMLSchema#string

P304

4548-4554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.8820

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Michael Pfreundschuh

Lorenz Trümper

Dirk Hasenclever

Hans-Konrad Müller-Hermelink

P577

2009-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26764225

http://www.w3.org/2001/XMLSchema#string

P698

19704068

http://www.w3.org/2001/XMLSchema#string

P921